2477 related articles for article (PubMed ID: 12810677)
1. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
2. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma.
Mitsuhashi N; Shimizu H; Ohtsuka M; Wakabayashi Y; Ito H; Kimura F; Yoshidome H; Kato A; Nukui Y; Miyazaki M
Hepatology; 2003 May; 37(5):1105-13. PubMed ID: 12717391
[TBL] [Abstract][Full Text] [Related]
3. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases.
Etoh T; Inoue H; Tanaka S; Barnard GF; Kitano S; Mori M
Cancer Res; 2001 Mar; 61(5):2145-53. PubMed ID: 11280779
[TBL] [Abstract][Full Text] [Related]
4. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors.
Stoeltzing O; Ahmad SA; Liu W; McCarty MF; Wey JS; Parikh AA; Fan F; Reinmuth N; Kawaguchi M; Bucana CD; Ellis LM
Cancer Res; 2003 Jun; 63(12):3370-7. PubMed ID: 12810673
[TBL] [Abstract][Full Text] [Related]
5. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis.
Goede V; Schmidt T; Kimmina S; Kozian D; Augustin HG
Lab Invest; 1998 Nov; 78(11):1385-94. PubMed ID: 9840613
[TBL] [Abstract][Full Text] [Related]
6. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling.
Currie MJ; Gunningham SP; Han C; Scott PA; Robinson BA; Harris AL; Fox SB
Clin Cancer Res; 2001 Apr; 7(4):918-27. PubMed ID: 11309342
[TBL] [Abstract][Full Text] [Related]
7. Expression of angiopoietin-2 and vascular endothelial growth factor in mice cerebral cortex after permanent focal cerebral ischemia.
Wang RG; Zhu XZ
Acta Pharmacol Sin; 2002 May; 23(5):405-11. PubMed ID: 11978190
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.
Larcher F; Robles AI; Duran H; Murillas R; Quintanilla M; Cano A; Conti CJ; Jorcano JL
Cancer Res; 1996 Dec; 56(23):5391-6. PubMed ID: 8968091
[TBL] [Abstract][Full Text] [Related]
9. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.
Zhang L; Yang N; Conejo-Garcia JR; Katsaros D; Mohamed-Hadley A; Fracchioli S; Schlienger K; Toll A; Levine B; Rubin SC; Coukos G
Clin Cancer Res; 2003 Jan; 9(1):264-72. PubMed ID: 12538479
[TBL] [Abstract][Full Text] [Related]
10. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.
Vajkoczy P; Farhadi M; Gaumann A; Heidenreich R; Erber R; Wunder A; Tonn JC; Menger MD; Breier G
J Clin Invest; 2002 Mar; 109(6):777-85. PubMed ID: 11901186
[TBL] [Abstract][Full Text] [Related]
11. NERF2, a member of the Ets family of transcription factors, is increased in response to hypoxia and angiopoietin-1: a potential mechanism for Tie2 regulation during hypoxia.
Christensen RA; Fujikawa K; Madore R; Oettgen P; Varticovski L
J Cell Biochem; 2002; 85(3):505-15. PubMed ID: 11967990
[TBL] [Abstract][Full Text] [Related]
12. Angiopoietin-1 and vascular endothelial growth factor expression in human esophageal cancer.
Nagata J; Kijima H; Hatanaka H; Tokunaga T; Kamochi J; Abe Y; Takagi A; Mine T; Yamazaki H; Nakamura M; Ueyama Y
Int J Mol Med; 2002 Oct; 10(4):423-6. PubMed ID: 12239588
[TBL] [Abstract][Full Text] [Related]
13. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas.
Eggert A; Ikegaki N; Kwiatkowski J; Zhao H; Brodeur GM; Himelstein BP
Clin Cancer Res; 2000 May; 6(5):1900-8. PubMed ID: 10815914
[TBL] [Abstract][Full Text] [Related]
14. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.
Hata K; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Miyazaki K
Gynecol Oncol; 2004 Apr; 93(1):215-22. PubMed ID: 15047239
[TBL] [Abstract][Full Text] [Related]
15. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
[TBL] [Abstract][Full Text] [Related]
16. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
[TBL] [Abstract][Full Text] [Related]
17. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.
Holash J; Wiegand SJ; Yancopoulos GD
Oncogene; 1999 Sep; 18(38):5356-62. PubMed ID: 10498889
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
Hata K; Osaki M; Dhar DK; Nakayama K; Fujiwaki R; Ito H; Nagasue N; Miyazaki K
Cancer Chemother Pharmacol; 2004 Jan; 53(1):68-74. PubMed ID: 14569416
[TBL] [Abstract][Full Text] [Related]
19. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.
Giuliani N; Colla S; Lazzaretti M; Sala R; Roti G; Mancini C; Bonomini S; Lunghi P; Hojden M; Genestreti G; Svaldi M; Coser P; Fattori PP; Sammarelli G; Gazzola GC; Bataille R; Almici C; Caramatti C; Mangoni L; Rizzoli V
Blood; 2003 Jul; 102(2):638-45. PubMed ID: 12649156
[TBL] [Abstract][Full Text] [Related]
20. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
